Sungwoo Ahn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sungwoo Ahn has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Nizar Jacques Bahlis
Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
47 shared publications - Paola Neri
University of Calgary
46 shared publications - Holly Lee
Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
45 shared publications - Lawrence H. Boise
Emory University
43 shared publications - Noemie Leblay
Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
43 shared publications - Benjamin Gabriel Barwick
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
42 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 15 January 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (3) , 964-977
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma
Tumor-intrinsic adaptations with emerging resistant clones following T cell-targeted immunotherapies pose a major barrier to durable remissions in multiple myeloma. Through integrated genomic, transcriptomic and epigenomic interrogation of clonal plasma cells, we observed antigenic drift in 68.4% of relapsed cases following anti-GPRC5D T cell-engager (TCE) therapy (n = 21). These escape events were driven by three distinct mutational mechanisms involving (1) focal to large biallelic deletions at the GPRC5D gene locus; (2) monoallelic deletion coupled with GPRC5D single-nucleotide variants or insertions/deletions (indels) on the remaining allele; as well as (3) epigenetic GPRC5D promoter/enhancer silencing. Beyond biallelic deletions resulting in complete antigenic loss, we demonstrate that GPRC5D single-nucleotide variants and indels mutate anti-GPRC5D TCE-binding epitopes or more commonly affect G-protein-coupled receptor family conserved motifs critical for protein membrane trafficking resulting in endoplasmic reticulum GPRC5D trapping. Multiple subclones bearing distinct genomic alterations at GPRC5D locus co-emerged within individual cases, depicting their convergent evolutionary trajectories. Of note, anti-GPRC5D TCEs with varying epitope specificity, affinity and valency differentially targeted mutant subclones, underscoring their nonredundant functional roles in overcoming resistance.
- 15 January 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (3) , 964-977
Top Cited PapersOpen AccessMultimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma
Tumor-intrinsic adaptations with emerging resistant clones following T cell-targeted immunotherapies pose a major barrier to durable remissions in multiple myeloma. Through integrated genomic, transcriptomic and epigenomic interrogation of clonal plasma cells, we observed antigenic drift in 68.4% of relapsed cases following anti-GPRC5D T cell-engager (TCE) therapy (n = 21). These escape events were driven by three distinct mutational mechanisms involving (1) focal to large biallelic deletions at the GPRC5D gene locus; (2) monoallelic deletion coupled with GPRC5D single-nucleotide variants or insertions/deletions (indels) on the remaining allele; as well as (3) epigenetic GPRC5D promoter/enhancer silencing. Beyond biallelic deletions resulting in complete antigenic loss, we demonstrate that GPRC5D single-nucleotide variants and indels mutate anti-GPRC5D TCE-binding epitopes or more commonly affect G-protein-coupled receptor family conserved motifs critical for protein membrane trafficking resulting in endoplasmic reticulum GPRC5D trapping. Multiple subclones bearing distinct genomic alterations at GPRC5D locus co-emerged within individual cases, depicting their convergent evolutionary trajectories. Of note, anti-GPRC5D TCEs with varying epitope specificity, affinity and valency differentially targeted mutant subclones, underscoring their nonredundant functional roles in overcoming resistance.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S2 from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Table S1: Clinical and sample data for patients in the study cohort. Table S2: GPRC5D and TNFRSF17 mutations from baseline samples in the CoMMpass dataset.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S2 from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Table S1: Clinical and sample data for patients in the study cohort. Table S2: GPRC5D and TNFRSF17 mutations from baseline samples in the CoMMpass dataset.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data, we could time genomic antigen escape in 4 of 11 patients with RRMM. In all cases, the biallelic loss was driven by genomic events acquired after exposure to BCMA- and GPCR5D-targeted CAR-T/TCE and not present at baseline. Longitudinal digital PCR analysis corroborated that resistance mutations were undetectable at therapy initiation but emerged preceding relapse. Among 752 newly diagnosed patients, only 2.7% and 9% had monoallelic inactivation of TNFRSF17 and GPCR5D, respectively, with no biallelic loss. Our findings suggest limited utility of mutational screening prior to CAR-T/TCE while underscoring the importance of dynamic surveillance during therapy.Significance:Multiple myeloma has been demonstrated to recurrently develop resistance to T-cell redirection via genomic antigen escape. By leveraging chemotherapy mutational signatures, we demonstrate that somatic antigen-escape mechanisms are uniformly acquired following treatment initiation and not selected from among preexisting clones, emphasizing the importance of dynamic longitudinal surveillance for their emergence.See related commentary by Kauer et al., p. 532
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data, we could time genomic antigen escape in 4 of 11 patients with RRMM. In all cases, the biallelic loss was driven by genomic events acquired after exposure to BCMA- and GPCR5D-targeted CAR-T/TCE and not present at baseline. Longitudinal digital PCR analysis corroborated that resistance mutations were undetectable at therapy initiation but emerged preceding relapse. Among 752 newly diagnosed patients, only 2.7% and 9% had monoallelic inactivation of TNFRSF17 and GPCR5D, respectively, with no biallelic loss. Our findings suggest limited utility of mutational screening prior to CAR-T/TCE while underscoring the importance of dynamic surveillance during therapy.Significance:Multiple myeloma has been demonstrated to recurrently develop resistance to T-cell redirection via genomic antigen escape. By leveraging chemotherapy mutational signatures, we demonstrate that somatic antigen-escape mechanisms are uniformly acquired following treatment initiation and not selected from among preexisting clones, emphasizing the importance of dynamic longitudinal surveillance for their emergence.See related commentary by Kauer et al., p. 532
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S3 from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Supplemental Figure 1: Swimmer plot of all cases described in the manuscript. Supplemental Figure 2: The 96-mutational profile of the truncal mutations per each of patients that can be timed, revealing a distinct, clonal melphalan signature profile (SBS-MM1/SBS99). Supplemental Figure 3: Additional Cases for which antigen escape timing was not possible.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S3 from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Supplemental Figure 1: Swimmer plot of all cases described in the manuscript. Supplemental Figure 2: The 96-mutational profile of the truncal mutations per each of patients that can be timed, revealing a distinct, clonal melphalan signature profile (SBS-MM1/SBS99). Supplemental Figure 3: Additional Cases for which antigen escape timing was not possible.
- 4 September 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (6) , 572-579
Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data, we could time genomic antigen escape in 4 of 11 patients with RRMM. In all cases, the biallelic loss was driven by genomic events acquired after exposure to BCMA- and GPCR5D-targeted CAR-T/TCE and not present at baseline. Longitudinal digital PCR analysis corroborated that resistance mutations were undetectable at therapy initiation but emerged preceding relapse. Among 752 newly diagnosed patients, only 2.7% and 9% had monoallelic inactivation of TNFRSF17 and GPCR5D, respectively, with no biallelic loss. Our findings suggest limited utility of mutational screening prior to CAR-T/TCE while underscoring the importance of dynamic surveillance during therapy. Significance: Multiple myeloma has been demonstrated to recurrently develop resistance to T-cell redirection via genomic antigen escape. By leveraging chemotherapy mutational signatures, we demonstrate that somatic antigen-escape mechanisms are uniformly acquired following treatment initiation and not selected from among preexisting clones, emphasizing the importance of dynamic longitudinal surveillance for their emergence. See related commentary by Kauer et al., p. 532
- 4 September 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (6) , 572-579
Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data, we could time genomic antigen escape in 4 of 11 patients with RRMM. In all cases, the biallelic loss was driven by genomic events acquired after exposure to BCMA- and GPCR5D-targeted CAR-T/TCE and not present at baseline. Longitudinal digital PCR analysis corroborated that resistance mutations were undetectable at therapy initiation but emerged preceding relapse. Among 752 newly diagnosed patients, only 2.7% and 9% had monoallelic inactivation of TNFRSF17 and GPCR5D, respectively, with no biallelic loss. Our findings suggest limited utility of mutational screening prior to CAR-T/TCE while underscoring the importance of dynamic surveillance during therapy. Significance: Multiple myeloma has been demonstrated to recurrently develop resistance to T-cell redirection via genomic antigen escape. By leveraging chemotherapy mutational signatures, we demonstrate that somatic antigen-escape mechanisms are uniformly acquired following treatment initiation and not selected from among preexisting clones, emphasizing the importance of dynamic longitudinal surveillance for their emergence. See related commentary by Kauer et al., p. 532
- Open Access
- 5 February 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (3) , 665
Author Correction: Highly secreted tryptophanyl tRNA synthetase 1 as a potential theranostic target for hypercytokinemic severe sepsis
- 5 February 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (3) , 665
Open AccessAuthor Correction: Highly secreted tryptophanyl tRNA synthetase 1 as a potential theranostic target for hypercytokinemic severe sepsis
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Differentially expressed genes and GSEA in OPM2 cells following shRNA knockdown of IKZF3.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Differentially expressed genes and GSEA in OPM2 cells following shRNA knockdown of IKZF3.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Univariate and multi-variate analysis of ETV4 expression in the CoMMpass NDMM patients treated with IMiD as part of front-line therapy (N=567).
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Univariate and multi-variate analysis of ETV4 expression in the CoMMpass NDMM patients treated with IMiD as part of front-line therapy (N=567).
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 5 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
ETV4 ChIP-seq binding sites in RPMI8226 cells.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 5 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
ETV4 ChIP-seq binding sites in RPMI8226 cells.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 4 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
JASPAR transcription factor binding motifs enriched in IKZF1-bound regions in RPMI8226 cells where the cognate transcription factor was expressed at greater than 1 FPKM and the FDR enrichment significance P ≤ 10e-10.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 4 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
JASPAR transcription factor binding motifs enriched in IKZF1-bound regions in RPMI8226 cells where the cognate transcription factor was expressed at greater than 1 FPKM and the FDR enrichment significance P ≤ 10e-10.